Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21195741rdf:typepubmed:Citationlld:pubmed
pubmed-article:21195741lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:21195741lifeskim:mentionsumls-concept:C0521119lld:lifeskim
pubmed-article:21195741lifeskim:mentionsumls-concept:C0019564lld:lifeskim
pubmed-article:21195741lifeskim:mentionsumls-concept:C1704448lld:lifeskim
pubmed-article:21195741lifeskim:mentionsumls-concept:C0028351lld:lifeskim
pubmed-article:21195741lifeskim:mentionsumls-concept:C0036751lld:lifeskim
pubmed-article:21195741lifeskim:mentionsumls-concept:C0040610lld:lifeskim
pubmed-article:21195741lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:21195741lifeskim:mentionsumls-concept:C0442805lld:lifeskim
pubmed-article:21195741lifeskim:mentionsumls-concept:C0444706lld:lifeskim
pubmed-article:21195741lifeskim:mentionsumls-concept:C0206056lld:lifeskim
pubmed-article:21195741lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:21195741pubmed:issue3lld:pubmed
pubmed-article:21195741pubmed:dateCreated2011-2-11lld:pubmed
pubmed-article:21195741pubmed:abstractTextTramadol is an atypical opioid with monoamine re-uptake inhibition properties. The aim of the current study was to compare, using in vivo microdialysis, the effect of tramadol on extracellular serotonin (5-HT) and noradrenaline (NA) levels in the rat ventral hippocampus with the effects of the dual 5-HT/NA inhibitors (SNRIs) duloxetine and venlafaxine, the tricyclic antidepressant clomipramine, the selective 5-HT re-uptake inhibitor (SSRI) citalopram, and the selective NA re-uptake inhibitor (NRI) reboxetine. It was found that tramadol, duloxetine and venlafaxine increased extracellular levels of both, 5-HT and NA, in a dose-dependent manner. Clomipramine also increased extracellular 5-HT and NA levels, however not dose-dependently in the tested dose range. Citalopram selectively increased extracellular 5-HT levels. Reboxetine increased extracellular NA levels and also to a minimal degree 5-HT levels. It can be concluded that, albeit less efficacious, the effects of tramadol on serotonergic and noradrenergic neurotransmission resemble those of the dual 5-HT and NA re-uptake inhibitors duloxetine, venlafaxine, and clomipramine, and are different from those of the SSRI citalopram and the NRI reboxetine.lld:pubmed
pubmed-article:21195741pubmed:languageenglld:pubmed
pubmed-article:21195741pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21195741pubmed:citationSubsetIMlld:pubmed
pubmed-article:21195741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21195741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21195741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21195741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21195741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21195741pubmed:statusMEDLINElld:pubmed
pubmed-article:21195741pubmed:monthMarlld:pubmed
pubmed-article:21195741pubmed:issn1872-7972lld:pubmed
pubmed-article:21195741pubmed:authorpubmed-author:Bloms-FunkePPlld:pubmed
pubmed-article:21195741pubmed:authorpubmed-author:TzschentkeT...lld:pubmed
pubmed-article:21195741pubmed:authorpubmed-author:DremencovEElld:pubmed
pubmed-article:21195741pubmed:authorpubmed-author:CremersT I...lld:pubmed
pubmed-article:21195741pubmed:copyrightInfoCopyright © 2011 Elsevier Ireland Ltd. All rights reserved.lld:pubmed
pubmed-article:21195741pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21195741pubmed:day3lld:pubmed
pubmed-article:21195741pubmed:volume490lld:pubmed
pubmed-article:21195741pubmed:ownerNLMlld:pubmed
pubmed-article:21195741pubmed:authorsCompleteYlld:pubmed
pubmed-article:21195741pubmed:pagination191-5lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:meshHeadingpubmed-meshheading:21195741...lld:pubmed
pubmed-article:21195741pubmed:year2011lld:pubmed
pubmed-article:21195741pubmed:articleTitleTramadol increases extracellular levels of serotonin and noradrenaline as measured by in vivo microdialysis in the ventral hippocampus of freely-moving rats.lld:pubmed
pubmed-article:21195741pubmed:affiliationGrünenthal GmbH, Global Preclinical Research and Development, 52099 Aachen, Germany. Petra.Bloms-Funke@grunenthal.comlld:pubmed
pubmed-article:21195741pubmed:publicationTypeJournal Articlelld:pubmed